CA Patent

CA2929199C — Crystalline beta-lactamase inhibitor

Assigned to Allecra Therapeutics SAS · Expires 2023-01-03 · 3y expired

What this patent protects

A crystalline compound of formula (I): Formula (I). The compound of formula (I) is a ß-lactamase inhibitor and may be administered in combination with an antibacterial agent for prevention or treatment of bacterial infection.

USPTO Abstract

A crystalline compound of formula (I): Formula (I). The compound of formula (I) is a ß-lactamase inhibitor and may be administered in combination with an antibacterial agent for prevention or treatment of bacterial infection.

Drugs covered by this patent

chembl-chembl1200962 (CEFEPIME HYDROCHLORIDE)

Patent Metadata

Patent number: CA2929199C
Jurisdiction: CA
Classification: —
Expires: 2023-01-03
Drug substance claim: No
Drug product claim: No
Assignee: Allecra Therapeutics SAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.